The narrow ridge from liver damage to hepatocarcinogenesis

References

[1] Fujiwara N,Koneru B.Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases.Hepatol Res2020;50:817-30

[2] Ertle J,Sowa JP.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.Int J Cancer2011;128:2436-43

[3] Wong SW,Chan WK.Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.JGH Open2018;2:235-41 PMCID:PMC6206984

[4] Araújo AR,Bedogni G,Bellentani S.Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future.Liver Int2018;38 Suppl 1:47-51

[5] Vernon G,Younossi ZM.Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.Aliment Pharmacol Ther2011;34:274-85

[6] Kanwal F,Mapakshi S.Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.Gastroenterology2018;155:1828-37.e2 PMCID:PMC6279617

[7] Younossi Z,Ong JP.Global Nonalcoholic Steatohepatitis CouncilNonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.Clin Gastroenterol Hepatol2019;17:748-55.e3

[8] Weinmann A,Koch S.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.BMC Cancer2015;15:210 PMCID:PMC4407550

[9] Dhanasekaran R,Roberts LR.Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances.F1000Res2016;5:F1000 Faculty Rev-879 PMCID:PMC4870992

[10] Daniele B,Megna AS.Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.Gastroenterology2004;127:S108-12

[11] Shang S,Ge S.Identification of osteopontin as a novel marker for early hepatocellular carcinoma.Hepatology2012;55:483-90 PMCID:PMC3914762

[12] Wang XY,Dubois S.Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.Hum Pathol2006;37:1435-41

[13] Liebman HA,Tong MJ.Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.N Engl J Med1984;310:1427-31

[14] Li D,Satomura S.AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.Clin Chim Acta2001;313:15-9

[15] Johnson PJ,Cox TF.The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.Cancer Epidemiol Biomarkers Prev2014;23:144-53

[16] Berhane S,Tada T.Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients.Clin Gastroenterol Hepatol2016;14:875-86.e6

[17] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-35.e4

[18] Venerito M,Canbay A.NEMESIS: noninferiority, individual-patient metaanalysis of selective internal radiation therapy with (90)y resin microspheres versus sorafenib in advanced hepatocellular carcinoma.J Nucl Med2020;61:1736-42

[19] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[20] Bruix J,Merle P.RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[21] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[22] Abou-Alfa GK,Cheng AL.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[23] Zhu AX,Yen CJ.REACH-2 study investigatorsRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[24] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905